Design Therapeutics, Inc.(DSGN)Earnings, Financials & Key RatiosDesign Therapeutics, Inc. (DSGN) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's cash position has plummeted to $12.8 million as of 2026Q1, creating a critical liquidity risk that necessitates immediate and likely dilutive financing to sustain operations.
Design Therapeutics, Inc. (DSGN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Design Therapeutics, Inc. (DSGN) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 28, 2026 | $0.29vs $0.36+19.4% | — |
| Q2 2026 | Mar 9, 2026 | $0.27vs $0.38+28.9% | — |
| Q4 2025 | Nov 5, 2025 | $0.30vs $0.34+11.8% | — |
| Q3 2025 | Aug 7, 2025 | $0.34vs $0.32-6.3% | — |
Recent stock market news and headlines for Design Therapeutics, Inc. (DSGN)
Design Therapeutics has its proprietary GeneTAC platform. This gives them a small-molecule way to target repeat-expansion diseases. Their main value driver and drug candidate is DT-216P2 for FA. DSGN's trial on DT-216P2 is RESTORE-FA. This trial produced data that I believe makes DT-216P2 much more credible.
Key metrics vs top competitors for Design Therapeutics, Inc. (DSGN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $14.85 | $927.49M | -12.17 | — | — | -30.7% | — | |
| $3.72 | $201.29M | -3.15 | -100% | — | -27.8% | — | |
| $104.91 | $20.02B | -95.37 | 17.69% | -6.4% | -8.66% | — | |
| $38.60 | $7.92B | -13.94 | — | — | -68.16% | — | |
| $26.07 | $3.26B | -200.54 | 91.34% | -0.57% | -1.41% | — | |
| $35.32 | $3.63B | -43.60 | 120.01% | -49.17% | -5.89% | — |
Design Therapeutics, Inc. (DSGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Design Therapeutics, Inc. (DSGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Apr 28, 2026·SEC
Apr 1, 2026·SEC
Mar 9, 2026·SEC
Get notified when DSGN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Design Therapeutics, Inc. (DSGN) stock FAQ — growth, dividends, profitability & financials explained
Design Therapeutics, Inc. (DSGN) reported a net loss of $69.7M for fiscal year 2025.
Design Therapeutics, Inc. (DSGN) has a return on equity (ROE) of -30.7%. Negative ROE indicates the company is unprofitable.
Design Therapeutics, Inc. (DSGN) had negative free cash flow of $54.1M in fiscal year 2025, likely due to heavy capital investments.
